News for Calithera Biosciences, Inc. (2CB.F)

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14) 10X ...

Today's Daily Dose brings you news about Lexicon's regulatory update on Sotagliflozin in heart failure; FDA approval of Pfizer's XALKORI in a new indication; Bicycle's pipeline progress update and Organogenesis' progress in knee osteoarthritis trial.

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 -- Calithera Biosciences, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the... | January 11, 2021

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology compan...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ja...

(RTTNews) - Today's Daily Dose brings you news about Pandion's phase Ia trial of autoimmune disease drug PT101 in healthy volunteers; Matinas BioP...

Today's Daily Dose brings you news about Pandion's phase Ia trial of autoimmune disease drug PT101 in healthy volunteers; Matinas BioPharma's anticipated milestone for this quarter; Calithera's disappointing results from phase II study of Telaglenastat in patients with renal cell carcinoma, Provention Bio's near-term regulatory catalyst; and disbanding of Haven Healthcare joint venture.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.61%

Toward the end of trading Monday, the Dow traded down 1.77% to 30,065.47 while the NASDAQ fell 1.83% to 12,652.84. The S&P also fell, dropping 1.83% to ...

Midway through trading Monday, the Dow traded down 1.72% to 30,080.25 while the NASDAQ fell 1.43% to 12,703.53. The S&P also fell, dropping 1.59% to ...